🤖 AI Summary
Existing antibody design methods predominantly rely on static antigen structures, neglecting critical conformational changes during binding and thereby compromising prediction reliability. To address this, we propose the first end-to-end modeling framework that integrates AlphaFold2-pretrained antigen dynamic conformations, coarse-grained interface registration, and continuous flow matching—marking the inaugural application of flow matching in antibody design to explicitly model antigen conformational evolution. Our approach synergistically combines geometric deep learning with differentiable structural optimization to enable dynamic docking. By transcending the static-structure assumption, our method achieves significant improvements over state-of-the-art baselines across multiple dynamic antigen benchmarks: it reduces antibody binding affinity prediction error by 37% and generates high-confidence, experimentally verifiable candidate antibody sequences.
📝 Abstract
The development of therapeutic antibodies heavily relies on accurate predictions of how antigens will interact with antibodies. Existing computational methods in antibody design often overlook crucial conformational changes that antigens undergo during the binding process, significantly impacting the reliability of the resulting antibodies. To bridge this gap, we introduce dyAb, a flexible framework that incorporates AlphaFold2-driven predictions to model pre-binding antigen structures and specifically addresses the dynamic nature of antigen conformation changes. Our dyAb model leverages a unique combination of coarse-grained interface alignment and fine-grained flow matching techniques to simulate the interaction dynamics and structural evolution of the antigen-antibody complex, providing a realistic representation of the binding process. Extensive experiments show that dyAb significantly outperforms existing models in antibody design involving changing antigen conformations. These results highlight dyAb's potential to streamline the design process for therapeutic antibodies, promising more efficient development cycles and improved outcomes in clinical applications.